Metabolism of carvedilol in dogs, rats, and mice. 1998

W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, USA.

The excretion and biotransformation of carvedilol [1-[carbazolyl-(4)-oxy]-3-[(2-methoxyphenoxyethyl)amino]-2-p ropanol], a new, multiple-action, neurohormonal antagonist that exhibits the combined pharmacological activities of beta-adrenoreceptor antagonism, vasodilation, and antioxidation, were investigated in dogs, rats, and mice. Carvedilol was absorbed well, and biliary secretion was predominant in each species. Carvedilol was metabolized extensively in each species, and elimination of unchanged compound was minor in bile duct-catheterized rats and dogs. In dogs, glucuronidation of the parent compound and hydroxylation of the carbazolyl ring, with subsequent glucuronidation, were the major metabolic pathways. Rats showed the simplest metabolite profile; the primary metabolites were formed by hydroxylation of the carbazolyl ring, with subsequent glucuronidation. Mice displayed the most complicated metabolite profile; glucuronidation of the parent compound and hydroxylation of either the carbazolyl or phenyl ring, with subsequent glucuronidation, were the major metabolic routes. O-Dealkylation was a minor pathway in all species examined.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D002227 Carbazoles Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000077261 Carvedilol A carbazole and propanol derivative that acts as a non-cardioselective beta blocker and vasodilator. It has blocking activity for ALPHA 1 ADRENERGIC RECEPTORS and, at higher doses, may function as a blocker of CALCIUM CHANNELS; it also has antioxidant properties. Carvedilol is used in the treatment of HYPERTENSION; ANGINA PECTORIS; and HEART FAILURE. It can also reduce the risk of death following MYOCARDIAL INFARCTION. BM 14190,BM-14190,Carvedilol Hydrochloride,Carvedilol, (+),Carvedilol, (+)-isomer,Carvedilol, (+-)-isomer,Carvedilol, (-),Carvedilol, (-)-isomer,Carvedilol, (R)-isomer,Carvedilol, (S)-isomer,Carvedilol, 14C-labeled,Coreg,Coropres,Dilatrend,Eucardic,Kredex,Querto,14C-labeled Carvedilol,BM14190,Carvedilol, 14C labeled
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic

Related Publications

W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
November 1998, Drug metabolism and disposition: the biological fate of chemicals,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
December 2010, Drug metabolism and disposition: the biological fate of chemicals,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
April 2010, Drug metabolism and disposition: the biological fate of chemicals,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
May 2014, Drug metabolism and disposition: the biological fate of chemicals,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
October 1977, Cancer treatment reports,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
August 2009, Drug metabolism and disposition: the biological fate of chemicals,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
May 1972, Toxicology and applied pharmacology,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
January 1992, Drug metabolism and disposition: the biological fate of chemicals,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
March 1979, The Japanese journal of antibiotics,
W H Schaefer, and J Politowski, and B Hwang, and F Dixon, and A Goalwin, and L Gutzait, and K Anderson, and C DeBrosse, and M Bean, and G R Rhodes
January 1971, Ceskoslovenska farmacie,
Copied contents to your clipboard!